Statement: ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial.
Primary_evidence: Inclusion Criteria:   Histologically confirmed breast cancer with accompanying pathology report;   Submit unstained representative tumor specimen, either as a paraffin block (preferred) or  10 unstained slides   Received at least 2 lines of systemic therapy in the advanced setting (for enzalutamide alone arm only);   Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;   Estimated life expectancy of at least 3 months Exclusion Criteria:   Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment;   Pregnant or lactating;   Known or suspected brain metastasis or leptomeningeal disease;   History of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;   For patients who are enrolled to receive enzalutamide plus anastrozole or exemestane or fulvestrant must not have received tamoxifen or any medication known to be a potent CYP3A4 inducer or inhibitor.